Salt Lake City, Utah (April 22, 2021) – BioUtah President and CEO, Kelvyn Cullimore, issued the following statement after House Democrat leaders released their drug pricing proposal, H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act, based upon similar legislation introduced in the 116th Congress. “Utah has a long and proud history of […]
ReddyPort has launched the ReddyPortTM Microphone and Controller, a first-of-its-kind device that includes a single-patient use microphone which integrates withReddyPortTM Elbow, providing an interface for application of continuous positive airway pressure (CPAP) or bi-level therapy. ReddyPort Microphone and Controller is a proprietary system enabling clinicians and patients to communicate clearly with one another and their […]
In case you missed the recent NOWCFO/Scalar webinar “What is Your Life Science or Bio Tech Company’s Worth?”, you can still pick up key takeaways from their informative power point. A successful life sciences company for sale can certainly be a hot commodity in today’s economy. Understanding your company’s value is vital to a lucrative […]
CAMBRIDGE, Mass., April 10, 2021 — Sumitomo Dainippon Pharma Oncology, Inc., a clinicalstage company focused on research and development for novel cancer therapeutics, today presented new findings on a range of investigational agents from the company’s pipeline at the American Association for Cancer Research (AACR) Virtual Annual Meeting I, taking place April 10-15, 2021. The […]
Congress is once again turning its attention to drug pricing, including the proposed use of foreign reference pricing models. Foreign reference pricing was part of the Lower Drug Costs Now Act passed by House Democrats in 2019 (also known as H.R. 3) and has resurfaced in legislation, the Prescription Drug Price Relief Act, recently introduced […]
On Wednesday, President Biden unveiled the first installment of his two-part Build Back Better plan – a sweeping $2.25 trillion infrastructure proposal billed as the American Jobs Plan. In addition to fixing highways, bridges and roads, which accounts for approximately 5% of the plan ( $620 billion), the measure calls for a myriad of administration […]
BioUtah has submitted a comment letter to CMS in response to concerns raised by the Biden administration around the Medicare Coverage of Innovative Technology (MCIT) rule finalized under President Trump on January 14. The MCIT program was set to take effect on March 15, but on March 12, in the form of an interim final […]
PhotoPharmics has announced its intent to leverage its FDA breakthrough device designation, potential streamlined Medicare coverage under CMS’ pending Medicare Coverage of Innovative Technology (MCIT) rule and global delivery channels to deliver its treatments for Parkinson’s and neurodegenerative diseases to individuals regardless of their location or income. Innovation not only brings improved treatments to address […]
Lehi-based Sumitomo Dainippon Pharma Oncology (SDP Oncology) recently presented new findings on a range of investigational agents from the company’s pipeline at the American Association for Cancer Research (AACR) Virtual Annual Meeting I. The data presented at the meeting include preclinical and Phase 1 clinical data evaluating the potential anti-cancer activity of the PKM2 activator […]
Fluidx’s regulatory and clinical affairs director will take the reins of the Regulatory, Compliance and Quality Committee, utilizing his expertise to help guide the regulatory and quality activities of BioUtah, the state’s premier life sciences trade association. Christopher Phillips, director of regulatory affairs and clinical affairs at Fluidx Medical Technology, has been appointed chair of […]
Xenter has announced its formal launch in Salt Lake City. Founded in 2020 by seasoned life sciences entrepreneur Richard J. Linder, Xenter is innovating new wireless technologies and techniques for the treatment of heart and vascular disease. The company’s next-generation devices will integrate functions that formerly required multiple costly devices. “We are bringing the world’s […]
Recursion Pharmaceuticals, Inc. today announced the pricing of its initial public offering of its Class A common stock at a price to the public of $18.00 per share. Recursion is offering 24,242,424 shares of its Class A common stock. The gross proceeds from the offering are expected to be $436.4 million. The shares are expected to […]